Topical antibacterial therapy for acne vulgaris

Drugs

Volumn 64, Issue 21, 2004, Pages 2389-2397

  Dreno, Brigitte ^a  

^a HÔTEL DIEU   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ADAPALENE; ANTIINFECTIVE AGENT; AZELAIC ACID; BENZOYL PEROXIDE; CLINDAMYCIN; ERYTHROMYCIN; ISOTRETINOIN; MECLOCYCLINE; NADIFLOXACIN; RETINOIC ACID; TETRACYCLINE; ZINC;

ACNE VULGARIS; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; ANTIINFLAMMATORY ACTIVITY; CLINICAL TRIAL; DRUG EFFICACY; DRUG SAFETY; DRY SKIN; ERYTHEMA; HUMAN; IRRITANT DERMATITIS; PRACTICE GUIDELINE; PRURITUS; PSEUDOMEMBRANOUS COLITIS; REVIEW; SKIN BURNING SENSATION; SKIN IRRITATION; SYSTEMATIC REVIEW;

ACNE VULGARIS; ADMINISTRATION, TOPICAL; ANTI-BACTERIAL AGENTS; BENZOYL PEROXIDE; DRUG COMBINATIONS; ERYTHROMYCIN; HUMANS; RETINOIDS; ZINC;

BACTERIA (MICROORGANISMS); PROPIONIBACTERIUM; PROPIONIBACTERIUM ACNES;

EID: 8144227146     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-200464210-00002     Document Type: Review

References (57)

1. Gollnick H. Current concepts of the pathogenesis of acne: implications for drug treatment. Drugs 2003; 63 (15): 1579-96
2. Gollnick H, Cunliffe W, Berson D, et al. Management of acne: a report from a global alliance to improve outcomes in acne. J Am Acad Dermatol 2003; 49 (1 Suppl): S1-2
3. Kim J, Ochoa MT, Krutzik SR, et al. Activation of toll-like receptor 2 in acne triggers inflammatory cytokine responses. J Immunol 2002; 169: 1535-41
4. Kurokawa I, Nishijima S, Kawabata S. Antimicrobial susceptibility of Propionibacterium acnes isolated from acne vulgaris. Eur J Dermatol 1999; 9: 25-8
5. Johnson BA, Nunley JR. Topical therapy for acne vulgaris: how do you choose the best drug for each patient? Postgrad Med 2000; 107: 69-80
6. Eady EA, Cove JH, Joanes DN, et al. Topical antibiotics for the treatment of acne vulgaris: a critical evaluation of the literature on their clinical benefit and comparative efficacy. J Dermatol Treat 1990; 1: 215-26
7. Holland KT, Bojar RA, Cunliffe WJ, et al. The effect of zinc and erythromycin on the growth of erythromycin-resistant and erythromycin-sensitive isolates of Propionibacterium acnes: an in-vitro study. Br J Dermatol 1992; 126: 505-9
8. Honzak L, Sentjurc M. Development of liposome encapsulated clindamycin for treatment of acne vulgaris. Pflugers Arch 2000; 440 (5 Suppl.): R44-5
9. Gollnick H, Schramm M. Topical drug treatment in acne. Dermatology 1998; 196: 119-25
10. Leyden J. Are 2 combined antimicrobial mechanisms better than 1 for the treatment of acne vulgaris? Clinical and antimicrobial results of a topical combination product containing 1% clindamycin and 5% benzoyl peroxide: introduction. Cutis 2001; 67 (2 Suppl.): 5-7
11. Patel VB, Misra AN, Marfatia YS. Preparation and comparative clinical evaluation of liposomal gel of benzoyl peroxide for acne. Drug Dev Ind Pharm 2001; 27: 863-9
12. Plewig G, Kligman AM. Acne and rosacea. 3rd ed. New York: Springer-Verlag, 2000
13. Rapaport M, Madli Puhvel S, Reinsmer RM. Evaluation of topical erythromycin and oral tetracycline in acne vulgaris. Cutis 1982; 30: 122-35
14. Eady EA, Holland KT, Cunliffe WJ, et al. Propionibacterium levels in patients with and without acne vulgaris. J Invest Dermatol 1975; 65: 382-4
15. Toyoda M, Morohashi M. An overview of topical antibiotics for acne treatment. Dermatology 1998; 196: 130-4
16. Akhavan A, Bershad S. Topical acne drugs: review of clinical properties, systemic exposure, and safety. Am J Clin Dermatol 2003; 4: 473-92
17. Hegemann L, Toso SM, Kitay K, et al. Anti-inflammatory actions of benzoyl peroxide: effects on the generation of reactive oxygen species by leucocytes and the activity of protein kinase C and calmodulin. Br J Dermatol 1994; 130: 569-75
18. Valacchi G, Rimbach G, Saliou C, et al. Effect of benzoyl peroxide on antioxidam status, NF-kappaB activity and interleukin-1alpha gene expression in human keratinocytes. Toxicology 2001; 165: 225-34
19. Basak PY, Gultekin F, Kilinc I, et al. The effect of benzoyl peroxide and benzoyl peroxide/erythromycin combination on the antioxidative defence system in papulopustular acne. Eur J Dermatol 2002; 12: 53-7
20. Burke B, Eady EA, Cunliffe WJ. Benzoyl peroxide versus topical erythromycin in the treatment of acne vulgaris. Br J Dermatol 1983; 108: 199-204
21. Chalker DK, Shalila A, Smith JG, et al. A double blind study of the effectiveness of a 3% erythromycin and 5% benzoyl peroxide combination in the treatment of acne vulgaris. J Am Acad Dermatol 1983; 9: 933-6
22. Gans EH, Kligman AM. Comparative efficacy of clindamycin and benzoyl peroxide for in vivo suppression of Propionibacterium acnes. J Dermatolog Treat 2002; 13: 107-10
23. Swinyer LJ, Baker MD, Swinyer TA. et al. A comparative study of benzoyl peroxide and clindamycin phosphate for treating acne vulgaris. Br J Dermatol 1988; 119: 615-22
24. Burkhart CG, Butcher C, Burkhart CN, et al. Effects of benzoyl peroxide on lipogenesis in sebaceous glands using an animal model. J Cutan Med Surg 2000; 4: 138-41
25. Gratton D, Raymond GP, Guertin-Larochelle S, et al. Topical clindamycin versus systemic tetracycline in the treatment of acne. J Am Acad Dermatol 1982; 7: 50-3
26. Katsambas A, Towarky AA, Stratigos J. Topical clindamycin phosphate compared with oral tetracycline in the treatment of acne vulgaris. Br J Dermatol 1987; 116: 387-91
27. Burton J and the Dermatology Research Group. A placebo-controlled study to evaluate the efficacy of topical tetracycline and oral tetracycline in the treatment of mild to moderate acne. J Int Med Res 1990; 18: 94-103
28. Braathen LS. Topical clindamycin versus oral tetracyclines and placebo in acne vulgaris. Scand J Infect Dis 1984; 43: 71-5
29. Dreno B, Reynaud A, Moyse D, et al. Erythromycin-resistance of cutaneous bacterial flora in acne. Eur J Dermatol 2001; 11: 549-53
30. Bojar RA, Eady EA, Jones CE, et al. Inhibition of erythromycin-resistant proponibacteria on the skin of acne patients by topical erythromycin with and without zinc. Br J Dermatol 1994; 130: 329-33
31. Habbema L, Koopmans B, Menke HE, et al. A 4% erythromycin and zinc combination (Zineryt) versus 2% erythromycin (Eryderm) in acne vulgaris: a randomized, double-blind comparative study. Br J Dermatol 1989; 121: 497-502
32. Schachner L, Pestana A, Kittles C. A clinical trial comparing the safety and efficacy of a topical erythromycin-zinc formulation with a topical clindamycin formulation. J Am Acad Dermatol 1990; 22 (3): 489-95
33. Feucht CL, Allen BS, Chalker DK, et al. Topical erythromycin with zinc in acne: a double-blind controlled study. J Am Acad Dermatol 1980; 3: 483-91
34. Zouboulis CC, Derumeaux L, Decroix J, et al. A multicentre, single-blind, randomized comparison of a fixed clindamycin phosphate/tretinoin gel formulation (Velac) applied once daily and a clindamycin lotion formulation (Dalacin T) applied twice daily in the topical treatment of acne vulgaris. Br J Dermatol 2000; 143: 498-505
35. Glass D, Boorman GC, Stables GI, et al. A placebo-controlled clinical trial to compare a gel containing a combination of isotretinoin (0.05%) and erythromycin (2%) with gels containing isotretinoin (0.05%) or erythromycin (2%) alone in the topical treatment of acne vulgaris. Dermatology 1999; 199: 242-7
36. Richter JR, Forstrom LR, Kiistala UO, et al. Efficacy of the fixed 1.2% clindamycin phosphate, 0.025% tretinoin gel formulation (Velac) and a proprietary 0.025% tretinoin gel formulation (Aberela) in the topical control of facial acne. J Eur Acad Dermatol Venereol 1998; 11: 227-33
37. Gupta AK, Lynde CW, Kunynetz RA, et al. A randomized, double-blind, multicenter, parallel group study to compare relative efficacies of the topical gels 3% erythromycin/5% benzoyl peroxide and 0.025% tretinoin/erythromycin 4% in the treatment of moderate acne vulgaris of the face. J Cutan Med Surg 2003; 7: 31-7
38. Chalker DK, Shalita A, Granham Smith J, et al. A double-blind study of the effectiveness of a 3% erythromycin and 5% benzoyl peroxide combination in the treatment of acne vulgaris. J Am Acad Dermatol 1983; 9: 933-6
39. Tschen Em Jones T. A new treatment for acne vulgaris combining benzoyl peroxide with clindamycin. J Drugs Dermatol 2002; 1: 153-7
40. Leyden JJ, Berger RS, Dunlap FE, et al. Comparison of the efficacy and safety of a combination topical gel formulation of benzoyl peroxide and clindamycin with benzoyl peroxide, clindamycin and vehicle gel in the treatments of acne vulgaris. Am J Clin Dermatol 2001; 2: 33-9
41. Ellis CN, Leyden J, Katz HI, et al. Therapeutic studies with a new combination benzoyl peroxide/clindamycin topical gel in acne vulgaris. Cutis 2001; 67 (2 Suppl): 13-20
42. Cunliffe WJ, Holland KT, Bojar R, et al. A randomized, double-blind comparison of a clindamycin gel with respect to microbiologie activity and clinical efficacy in the topical treatment of acne vulgaris. Clin Ther 2002; 24: 1117-33
43. Parry MF, Rha CK. Pseudomembranous colitis caused by topical clindamycin phosphate. Arch Dermatol 1986; 122: 583-4
44. Fisher AA. Adverse reactions topical clindamycin, erythromycin and tetracyclin. Cutis 1983; 32: 415-9
45. Krowchuk DP. Treating acne: a practical guide. Med Clin North Am 2000; 84: 811-28
46. White GM. Acne therapy. Adv Dermatol 1999; 14: 29-57
47. Mills Jr O, Thornsberry C, Cardin CW, et al. Bacterial resistance and therapeutic outcome following three months of topical acne therapy with 2% erythromycin gel versus its vehicle. Acta Derm Venereol 2002; 82: 260-5
48. Ross JI, Snelling AM, Carnegie E, et al. Antibiotic-resistant acne: lessons from Europe. Br J Dermatol 2003; 148: 467-78
49. Ross JI, Snelling AM, Eady EA, et al. Phenotypic and genotypic characterization of antibiotic-resistant Propionibacterium acnes isolated from acne patients attending dermatology clinics in Europe, the USA, Japan and Australia. Br J Dermatol 2001; 144: 339-46
50. Leyden JJ, McGinley KJ, Cavalieri S, et al. Propionibacterium acnes resistance to antibiotics in acne patients. J Am Acad Dermatol 1983; 8: 41-5
51. Eady EA, Cove JH, Holland KT, et al. Erythromycin resistant propionibacleria in antibiotic treated acne patients: association with therapeutic failure. Br J Dermatol 1989; 121: 51-7
52. Leyden JJ. Current issues in antimicrobial therapy for the treatment of acne. J Eur Acad Dermatol Venereol 2001; 15 Suppl. 3: 51-5
53. Ross JI, Snelling AM, Carnegie E, et al. Antibiotic-resistant strain acne lesions from Europe. Br J Dermatol 2003; 148: 467-78
54. Knutson DD, Swinyer LI, Smoot WH. Meclocycline sulfosalicylate: topical antibiotic agent for the treatment of acne vulgaris. Cutis 1981; 27: 203-10
55. Kurokawa I, Akamatsu H, Nishijima S, et al. Clinical and bacteriologic evaluation of OPC-7251 in patients with acne: a double-blind group comparison study versus cream base. J Am Acad Dermatol 1991; 25: 674-81
56. Vogt K, Hanhn H, Hermann J, et al. Antimicrobial evaluation of nadifloxacin (OPC-7251), a new topical quinolone, in acne vulgaris. Drugs 1995; 49 (2 Suppl.): 266-8
57. Graupe K, Cunliffe W, Gollnick H, et al. Efficacy and safety of topical acid azelaic (20% cream): an overview of results from European clinical trials and experimental reports. Cutis 1996; 57 (1 Suppl.): 13-9